Özgür Sirkeci, Emel Erkuş Sirkeci, Belma Taşel

Rivaroxaban-induced acute pancreatitis

ISSN: 2149-3189
Yayın Aralığı: 6
Başlangıç: 2015
Yayıncı: Prusa Medikal Yayıncılık Limited Şirketi

Rivaroxaban is a direct factor Xa inhibitor and has been safely used since 2008. It is used for the detection ofatrial fibrillation and venous thromboembolism. Pancreatitis is one of the rare but dangerous side effects ofrivaroxaban. The case of a 53-year-old female patient that developed in the third month of drug usage wasevaluated, and it was confirmed after a full analysis was conducted that excluded all other factors, such asbiliary calculus, alcohol usage, hypertriglyceridemia, biochemical parameters, ultrasonography and computedtomography that the patient’s condition was caused by the use of Rivaroxaban. The aim of this case presentationis to indicate that awareness should be increased regarding the risks of using the drug Rivaroxaban, as it couldlead to drug-induced pancreatitis, even though this is rare.

PDF

___

[1] Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am 2008;92:889-923.
[2] Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis:an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-61.
[3] http://www.ehealthme.com/ds/xarelto/pancreatitis/
[4] Tenner S. Drug induced acute pancreatitis: Does it exist? World J Gastroenterol 2014;20:16529-34.
[5] Hung WY, Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol 2014;5:405-15.